<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754350</url>
  </required_header>
  <id_info>
    <org_study_id>ERGO2</org_study_id>
    <nct_id>NCT01754350</nct_id>
  </id_info>
  <brief_title>Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma</brief_title>
  <acronym>ERGO2</acronym>
  <official_title>Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TAVARLIN (Darmstadt, Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased glucose metabolism is characteristic for solid tumors. Thereby, glucose is&#xD;
      important for the generation of ATP, supply of anabolic substrates and defense against&#xD;
      reactive oxygen species in tumor cells. In preclinical models, restricting glucose&#xD;
      availability using a ketogenic diet, calorie-restriction or transient fasting inhibits tumor&#xD;
      growth.&#xD;
&#xD;
      Therefore, the purpose of the study is to evaluate whether a calorie-restricted, ketogenic&#xD;
      diet and transient fasting can enhance the efficacy of reirradiation in patients with&#xD;
      recurrent glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free-survival</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free-survival rates 6 months after reirradiation based on response assessment in neuro-oncology criteria (RANO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility Measured as Median Number of Days on Diet Per Patient and Average Calorie and Carbohydrate Intake Per Day During Day 1-9</measure>
    <time_frame>day 1-12</time_frame>
    <description>Feasibility of the calorie-restricted, ketogenic diet and the transient fasting measured as median number of days on diet per patient and average calorie and carbohydrate intake per day during day 1-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Defined as Number of Patients With Adverse Events</measure>
    <time_frame>day 1-12</time_frame>
    <description>Safety and tolerability of the calorie-restricted, ketogenic diet and the transient fasting as defined as number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free-survival</measure>
    <time_frame>1 month, 3 months</time_frame>
    <description>progression-free-survival rates 1 month and 3 month after reirradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
    <description>overall survival after the reirradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Seizures</measure>
    <time_frame>day 1-12</time_frame>
    <description>frequency of seizures at day 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketosis</measure>
    <time_frame>day 1-12</time_frame>
    <description>urine and blood ketosis and metabolic parameters (glucose, insulin, IGF-1) during day 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the EORTC Quality of Life Questionnaire</measure>
    <time_frame>day 1-12</time_frame>
    <description>Quality of life at day 1-12 as measured by the EORTC Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>day 1-12</time_frame>
    <description>depression as measured by SCL-90 at day 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention</measure>
    <time_frame>day 1-12</time_frame>
    <description>attention as measured by d2-testing at day 1-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>1 month</time_frame>
    <description>response assessment 1 month after reirradiation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>ketogenic diet and transient fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calorie-restricted, ketogenic diet and transient fasting during reirradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard nutrition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nutrition according to recommendations of the German society for nutrition during reirradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calorie-restricted ketogenic diet and transient fasting</intervention_name>
    <description>On day 1-3 and day 7-9, restriction of carbohydrates to &lt; 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by &quot;Tavarlin&quot;.</description>
    <arm_group_label>ketogenic diet and transient fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>standard nutrition</intervention_name>
    <description>nutrition as recommended by the german society for nutrition, 30 kcal/kg per day</description>
    <arm_group_label>standard nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;= 18 years&#xD;
&#xD;
          -  recurrence of a histologically confirmed glioblastoma or gliosarcoma&#xD;
&#xD;
          -  at least 6 months after first surgery&#xD;
&#xD;
          -  at least 6 months after first radiotherapy&#xD;
&#xD;
          -  interdisciplinary recommendation for reirradiation&#xD;
&#xD;
          -  karnofsky performance status &gt;= 60, ECOG &lt;= 2&#xD;
&#xD;
          -  creatinine &lt;= 2,0 mg/dl, urea &lt;= 100 mg/dl&#xD;
&#xD;
          -  ALAT, ASAT &lt;= 7x upper normal limit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  bowel obstruction, subileus&#xD;
&#xD;
          -  insulin-dependent diabetes&#xD;
&#xD;
          -  decompensated heart failure (NYHA &gt; 2)&#xD;
&#xD;
          -  myocardial infarction within the last 6 months, symptomatic atrial fibrillation&#xD;
&#xD;
          -  severe acute infection&#xD;
&#xD;
          -  malnutrition, cachexia&#xD;
&#xD;
          -  other medical conditions that might increase the risk of the dietary intervention&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  uncontrolled thyroid function&#xD;
&#xD;
          -  pancreatic insufficiency&#xD;
&#xD;
          -  dementia or other clinically relevant alterations of the mental status which could&#xD;
             impair the ability of the patient to apply to the diet or understand the informed&#xD;
             consent of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Senckenberg Institute of Neurooncology</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <results_first_submitted>March 28, 2021</results_first_submitted>
  <results_first_submitted_qc>May 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2021</results_first_posted>
  <last_update_submitted>May 30, 2021</last_update_submitted>
  <last_update_submitted_qc>May 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Johannes Rieger</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>ketogenic diet</keyword>
  <keyword>glioma</keyword>
  <keyword>fasting</keyword>
  <keyword>reirradiation</keyword>
  <keyword>nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT01754350/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketogenic Diet and Transient Fasting</title>
          <description>Calorie-restricted, ketogenic diet and transient fasting during reirradiation&#xD;
calorie-restricted ketogenic diet and transient fasting: On day 1-3 and day 7-9, restriction of carbohydrates to &lt; 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by &quot;Tavarlin&quot;.</description>
        </group>
        <group group_id="P2">
          <title>Standard Nutrition</title>
          <description>nutrition according to recommendations of the German society for nutrition during reirradiation&#xD;
standard nutrition: nutrition as recommended by the german society for nutrition, 30 kcal/kg per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketogenic Diet and Transient Fasting</title>
          <description>Calorie-restricted, ketogenic diet and transient fasting during reirradiation&#xD;
calorie-restricted ketogenic diet and transient fasting: On day 1-3 and day 7-9, restriction of carbohydrates to &lt; 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by &quot;Tavarlin&quot;.</description>
        </group>
        <group group_id="B2">
          <title>Standard Nutrition</title>
          <description>nutrition according to recommendations of the German society for nutrition during reirradiation&#xD;
standard nutrition: nutrition as recommended by the german society for nutrition, 30 kcal/kg per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="39" upper_limit="71"/>
                    <measurement group_id="B2" value="58" lower_limit="26" upper_limit="75"/>
                    <measurement group_id="B3" value="57" lower_limit="26" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free-survival</title>
        <description>Progression-free-survival rates 6 months after reirradiation based on response assessment in neuro-oncology criteria (RANO)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketogenic Diet and Transient Fasting</title>
            <description>Calorie-restricted, ketogenic diet and transient fasting during reirradiation&#xD;
calorie-restricted ketogenic diet and transient fasting: On day 1-3 and day 7-9, restriction of carbohydrates to &lt; 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by &quot;Tavarlin&quot;.</description>
          </group>
          <group group_id="O2">
            <title>Standard Nutrition</title>
            <description>nutrition according to recommendations of the German society for nutrition during reirradiation&#xD;
standard nutrition: nutrition as recommended by the german society for nutrition, 30 kcal/kg per day</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free-survival</title>
          <description>Progression-free-survival rates 6 months after reirradiation based on response assessment in neuro-oncology criteria (RANO)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility Measured as Median Number of Days on Diet Per Patient and Average Calorie and Carbohydrate Intake Per Day During Day 1-9</title>
        <description>Feasibility of the calorie-restricted, ketogenic diet and the transient fasting measured as median number of days on diet per patient and average calorie and carbohydrate intake per day during day 1-9</description>
        <time_frame>day 1-12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability as Defined as Number of Patients With Adverse Events</title>
        <description>Safety and tolerability of the calorie-restricted, ketogenic diet and the transient fasting as defined as number of patients with adverse events</description>
        <time_frame>day 1-12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free-survival</title>
        <description>progression-free-survival rates 1 month and 3 month after reirradiation</description>
        <time_frame>1 month, 3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>overall survival after the reirradiation</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Seizures</title>
        <description>frequency of seizures at day 1-12</description>
        <time_frame>day 1-12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ketosis</title>
        <description>urine and blood ketosis and metabolic parameters (glucose, insulin, IGF-1) during day 1-12</description>
        <time_frame>day 1-12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the EORTC Quality of Life Questionnaire</title>
        <description>Quality of life at day 1-12 as measured by the EORTC Quality of Life Questionnaire</description>
        <time_frame>day 1-12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression</title>
        <description>depression as measured by SCL-90 at day 1-12</description>
        <time_frame>day 1-12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Attention</title>
        <description>attention as measured by d2-testing at day 1-12</description>
        <time_frame>day 1-12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response</title>
        <description>response assessment 1 month after reirradiation</description>
        <time_frame>1 month</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All, even non-serious adverse events, were monitored at start of treatment until end of intervention at day 12 to assess procedure-specific adverse events. After day 12, the prespecified secondary end point and adverse event &quot;epileptic seizures&quot;), and all serious adverse events were documented until the end of the study of individual patients (until primary end points was reached).</time_frame>
      <desc>Few minor adverse events are not listed seperately because some of these occured in the same patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ketogenic Diet and Transient Fasting</title>
          <description>Calorie-restricted, ketogenic diet and transient fasting during reirradiation&#xD;
calorie-restricted ketogenic diet and transient fasting: On day 1-3 and day 7-9, restriction of carbohydrates to &lt; 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by &quot;Tavarlin&quot;.</description>
        </group>
        <group group_id="E2">
          <title>Standard Nutrition</title>
          <description>nutrition according to recommendations of the German society for nutrition during reirradiation&#xD;
standard nutrition: nutrition as recommended by the german society for nutrition, 30 kcal/kg per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>epileptic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Others</sub_title>
                <description>headache, nausea or possible epileptic seizures with short lasting aphasia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Johannes Rieger</name_or_title>
      <organization>JohannWGUH</organization>
      <phone>+4969630187711</phone>
      <email>j.rieger@uni-tuebingen.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

